Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622379 | PMC |
| http://dx.doi.org/10.4103/2152-7806.109525 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Towards a definition of an existential approach in cancer patients: a co-produced scoping review.
PLoS One
September 2025
Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.
Background: Attention to existential needs has become part of daily treatment. Studies have described the concepts of existential experiences and existential interventions. However, a consensus or conceptual clarity regarding an existential approach in cancer patients is currently missing.
View Article and Find Full Text PDFAltered Neurocritical Care Management of Patients with Severe Traumatic Brain Injury Following Changed Positions of the Zero-Reference Points for Intracranial and Arterial Pressure Measurement.
Neurocrit Care
September 2025
Department of Clinical Sciences Lund, Neurosurgery, Department of Clinical Sciences, Lund University, Lund, Sweden.
Background: Many traumatic brain injury (TBI) treatment protocols, including the Lund concept, advocate the highest point of the subarachnoid space (typically the vertex) as the zero-reference point for intracranial pressure (ICP) and the level of the right atrium as the zero-reference point for mean arterial blood pressure (MAP). In 2017, at the Department of Neurosurgery in Lund, Sweden, the zero-reference points for ICP and MAP were both changed to the external auditory meatus (EAM), thus altering the calculated cerebral perfusion pressure (CPP) levels. We hypothesized that the ICP and MAP levels obtained from the different zero-reference points resulted in altered neurocritical care management and/or patient outcome.
View Article and Find Full Text PDFExtrachromosomal DNA-Driven Oncogene Spatial Heterogeneity and Evolution in Glioblastoma.
Cancer Discov
September 2025
Evolutionary Dynamics Group, Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Unlabelled: Oncogenes amplified on extrachromosomal DNA (ecDNA) contribute to treatment resistance and poor survival across cancers. Currently, the spatiotemporal evolution of ecDNA remains poorly understood. In this study, we integrate computational modeling with samples from 94 treatment-naive human glioblastomas (GBM) to investigate the spatiotemporal evolution of ecDNA.
View Article and Find Full Text PDFAdvanced Biomaterial Delivery of Hypoxia-Conditioned Extracellular Vesicles (EVs) as a Therapeutic Platform for Traumatic Brain Injury.
Adv Sci (Weinh)
September 2025
Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
Traumatic Brain Injury (TBI) is a common and debilitating injury, causing long-lasting neurological deficits. Current therapeies for recovery remain inadequate, undersing the urgent need for innovative interventions. In this study, a novel therapeutic approach is introduced that delivers extracellular vesicles (EVs) derived from human-induced pluripotent stem cell-derived neural progenitor cells (hiPSC-NPCs) with a gelatin-based injectable bioorthogonal hydrogel (BIOGEL).
View Article and Find Full Text PDFUnraveling Etiological Indications and Therapeutic Implications of Familial Cerebral Cavernous Malformations in the Dawn of Gene Therapy for Monogenic Conditions.
Curr Gene Ther
August 2025
State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing 100191, China.
Cerebral Cavernous Malformations (CCMs) are vascular anomalies in the central nervous system that arise from both genetic and non-genetic factors, and can cause hemorrhage, seizures, and neurological deficits. Approximately 80% of CCMs are sporadic, while 20% are Familial (FCCMs), an autosomal dominant, monogenic disorder characterized by multiple lesions and severe clinical manifestations. Over the past three decades, linkage analyses have identified KRIT1/CCM1, MGC4607/CCM2, and PDCD10/CCM3 as major pathogenic genes in FCCMs.
View Article and Find Full Text PDF